Technical Analysis for NUVL - Nuvalent, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Gapped Down | Weakness | 0.00% | |
| Shooting Star Candlestick | Bearish | -1.68% | |
| NR7 | Range Contraction | -1.68% | |
| MACD Bullish Signal Line Cross | Bullish | -2.26% | |
| Gapped Up | Strength | -2.26% | |
| Oversold Stochastic | Weakness | -2.26% | |
| Slingshot Bearish | Bearish Swing Setup | 2.45% | |
| 200 DMA Support | Bullish | 2.45% | |
| Oversold Stochastic | Weakness | 2.45% | |
| Slingshot Bearish | Bearish Swing Setup | 5.27% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | about 19 hours ago |
| 10 DMA Support | about 22 hours ago |
| Gapped Down (Full) | about 22 hours ago |
| Down 3% | about 22 hours ago |
| Shooting Star Candlestick Entry | about 22 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/09/2024
Nuvalent, Inc. Description
Nuvalent, Inc., a preclinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor, designed to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and also remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors; and NVL-655, a brain-penetrant ALK-selective inhibitor, designed to inhibit ALK fusions that express the normal ALK kinase domain without any drug-resistant mutations and also remain active in the presence of mutations conferring resistance to first, second, and third generation ALK inhibitors. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Organic Compounds Chemical Compounds Tyrosine Kinase Receptors Preclinical Stage Biopharmaceutical Anaplastic Lymphoma Kinase
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 89.39 |
| 52 Week Low | 33.03 |
| Average Volume | 504,735 |
| 200-Day Moving Average | 62.98 |
| 50-Day Moving Average | 77.07 |
| 20-Day Moving Average | 68.30 |
| 10-Day Moving Average | 65.10 |
| Average True Range | 3.00 |
| RSI (14) | 39.39 |
| ADX | 39.12 |
| +DI | 14.28 |
| -DI | 30.45 |
| Chandelier Exit (Long, 3 ATRs) | 69.13 |
| Chandelier Exit (Short, 3 ATRs) | 70.81 |
| Upper Bollinger Bands | 76.41 |
| Lower Bollinger Band | 60.19 |
| Percent B (%b) | 0.36 |
| BandWidth | 23.74 |
| MACD Line | -3.30 |
| MACD Signal Line | -3.70 |
| MACD Histogram | 0.3949 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 69.21 | ||||
| Resistance 3 (R3) | 69.01 | 67.77 | 68.68 | ||
| Resistance 2 (R2) | 67.77 | 66.97 | 67.87 | 68.51 | |
| Resistance 1 (R1) | 66.92 | 66.48 | 67.35 | 67.12 | 68.33 |
| Pivot Point | 65.68 | 65.68 | 65.89 | 65.78 | 65.68 |
| Support 1 (S1) | 64.83 | 64.88 | 65.26 | 65.03 | 63.81 |
| Support 2 (S2) | 63.59 | 64.39 | 63.69 | 63.63 | |
| Support 3 (S3) | 62.74 | 63.59 | 63.46 | ||
| Support 4 (S4) | 62.94 |
